Silatecan
Based on 1 Customer Validation
Silatecan (AR-67) is a blood-brain barrier-permeable derivative of Camptothecin (HY-16560), DNA topoisomerase I inhibitor, an anticancer agent, and a radiosensitizer. Silatecan potently radiosensitizes wild-type p53 gliomas. Silatecan can be used in research related to glioma, leukemia, non-small cell lung cancer, colon cancer, ovarian cancer, renal cancer, prostate cancer, breast cancer, cervical cancer, gastric cancer, nasopharyngeal cancer, and uterine cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 96.62%
- CAS. Nr.: 220913-32-6
- Formel: C26H30N2O5Si
- Molecular Weight:478.61
-
Speicherung:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle Topoisomerase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Topoisomerase I |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-435 | IC50 |
14 nM
Compound: 14
|
Inhibition against MDA-MB-435 S human breast cancer cells in the absence of albumin
Inhibition against MDA-MB-435 S human breast cancer cells in the absence of albumin
|
[PMID: 11052802] |
| Tumor Cell line | GI50 |
21 nM
Compound: 14
|
Mean GI50 against variety of human tumor cell lines
Mean GI50 against variety of human tumor cell lines
|
[PMID: 11052802] |
Silatecan (10 μg/mL; 0-6 h) exhibits better lactone stability in BALB/c mouse plasma than CPT-11 (HY-16562), Topotecan (HY-13768) and CPT (HY-16560), with a 50% degradation time of 30 min, and 20% of its lactone form remains after 6 h of incubation[2].
Silatecan (at various concentrations; 72 h) potently inhibits the growth of multiple cancer cell lines, including drug-resistant sublines (e.g., gastric cancer MKN45, nasopharyngeal carcinoma TW-039)[2].
Silatecan (0.001-10 μg/mL; 96 h) inhibits the proliferation of colorectal cancer SW480 cells, gastric cancer MKN45 cells, nasopharyngeal carcinoma TW039 cells, uterine cancer MES-SA cells, and Doxorubicin (HY-15142A)-resistant MES-SA/Dx5 cells in vitro tissue culture in a concentration-dependent manner, with IC50 values ranging from 0.03 μM (TW039) to 2.21 μM (SW480)[2].
Silatecan (0.1-1.0 μM; 30 min) potently radiosensitizes wild-type p53 glioma D54-MG cells by eliminating the shoulder region of radiation survival curves; its SER reaches 1.4 at concentrations of 0.1 or 0.2 μM[3].
Silatecan (0.1 μM; 30 min) mildly radiosensitizes glioma T98G cells carrying mutant p53, with an SER of 1.2 at the concentration of 0.1 μM, but its sensitizing effect is weaker than that on D54-MG cells carrying wild-type p53[3].
Silatecan (30 min) is a potent cytotoxic agent in wild-type TOP1 Chinese hamster lung fibroblast DC3F cells (LD50 = 0.05 μM)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human cervical KB, Topo I-overexpressed KB-100, P-gp170/MDR-overexpressed vinblastine-resistant KB-VIN10, P-gp170/MDR-overexpressed paclitaxel-resistant KB-TAX50, gastric MKN45, colorectal SW480, breast MCF-7, hepatic HepG2, nasopharyngeal TW-039, uterine MES-SA, doxorubicin-resistant uterine MES-SA/Dx5
-
Concentration:Various concentrations
-
Incubation Time:72 h
-
Result:Exhibited IC50 values of 35 nM (KB), 750 nM (KB-100), 2271 nM (KB-VIN10), 50 nM (KB-TAX50).
-
Cell Line:human glioma D54-MG cells
-
Concentration:5 μM, 10 μM
-
Incubation Time:30 min
-
Result:Depleted free cellular TOP1 in a dose-dependent manner, indicating stimulation of covalent TOP1-DNA complex formation.
Was 10-fold more potent than camptothecin for this effect, as 5 μM induced greater TOP1 depletion than 50 μM camptothecin.
Left TOP2 and β-actin levels unaffected, demonstrating specificity for TOP1.
| Species | Dose | Route | T1/2 (Distribution) | T1/2β | CL | Vdss |
|---|---|---|---|---|---|---|
| Mice[2] | 8 mg/kg | i.v. | 8 min | 33 min | 37 mL/min/kg | 0.7 L/kg |
Silatecan (3-10 mg/kg; i.v.; daily; two 5-consecutive-day cycles) exerts dose-dependent in vivo antitumor activity against subcutaneous human colorectal SW480 xenografts in male BALB/c nude mice, with significant tumor growth inhibition observed at 3 mg/kg and 10 mg/kg intravenous doses[2].
Silatecan (3.3-10 mg/kg; i.v.; daily; two 5-consecutive-day cycles) exerts dose-dependent in vivo antitumor activity against subcutaneous gastric MKN45 xenografts in male BALB/c nude mice, with significant tumor growth inhibition observed at 3.3 mg/kg and 10 mg/kg intravenous doses[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice[1]
-
Dosage:3 mg/kg/day; 10 mg/kg/day; 30 mg/kg/day
-
Administration:daily; 5 days (3 mg/kg, 10 mg/kg); daily; four 21-day cycles (10 mg/kg); daily; two cycles (30 mg/kg)
-
Result:Achieved 61% tumor growth inhibition at day 28 post-implantation.
Achieved 73% tumor growth inhibition at day 28 post-implantation.
Kept mice progression-free for over 90 days before tumor regrowth after treatment cessation.
Induced complete tumor regression in all animals, even when initiated after large tumors had developed.
Caused no overt toxicity in any treated animals.
-
Animal Model:BALB/c nude (male, adult, human colorectal SW480 cancer cells implanted subcutaneously)[2]
-
Dosage:3 mg/kg; 10 mg/kg
-
Administration:i.v.; daily; two 5-consecutive-day cycles (days 1-5 and days 22-26)
-
Result:Dose-dependently suppressed the growth of human colorectal SW480 tumor xenografts, with significant differences in tumor size compared to the vehicle control group (p < 0.05) by day 60 post-dosing.
-
Animal Model:BALB/c nude (male, adult, human gastric MKN45 cancer cells implanted subcutaneously)[2]
-
Dosage:3.3 mg/kg; 10 mg/kg
-
Administration:i.v.; daily; two 5-consecutive-day cycles (days 1-5 and days 22-26)
-
Result:Dose-dependently suppressed the growth of human gastric MKN45 tumor xenografts, with significant differences in tumor size compared to the vehicle control group (p < 0.05) by day 40 post-dosing.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 220913-32-6
-
Appearance Solid
-
Molecular Weight 478.61
-
Formel C26H30N2O5Si
-
Color Yellow to brown
-
SMILES
O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C([Si](C)(C(C)(C)C)C)C5=CC(O)=CC=C5N=C4C3=C2)=O
-
Synonyms
AR-67; DB 67
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Lösungsmittel & Löslichkeit
DMSO : ≥ 100 mg/mL (208.94 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.22 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (5.22 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
Verweise
[1]. Bom D, et al. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. J Control Release. 2001;74(1-3):325-333. [Content Brief]
[2]. Yeh TK, et al. Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91. Pharmacol Res. 2010;61(2):108-115. [Content Brief]
[3]. Chen AY, et al. Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer. Mol Cancer Ther. 2005;4(2):317-324. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0894 mL | 10.4469 mL | 20.8938 mL | 52.2346 mL |
| 5 mM | 0.4179 mL | 2.0894 mL | 4.1788 mL | 10.4469 mL | |
| 10 mM | 0.2089 mL | 1.0447 mL | 2.0894 mL | 5.2235 mL | |
| 15 mM | 0.1393 mL | 0.6965 mL | 1.3929 mL | 3.4823 mL | |
| 20 mM | 0.1045 mL | 0.5223 mL | 1.0447 mL | 2.6117 mL | |
| 25 mM | 0.0836 mL | 0.4179 mL | 0.8358 mL | 2.0894 mL | |
| 30 mM | 0.0696 mL | 0.3482 mL | 0.6965 mL | 1.7412 mL | |
| 40 mM | 0.0522 mL | 0.2612 mL | 0.5223 mL | 1.3059 mL | |
| 50 mM | 0.0418 mL | 0.2089 mL | 0.4179 mL | 1.0447 mL | |
| 60 mM | 0.0348 mL | 0.1741 mL | 0.3482 mL | 0.8706 mL | |
| 80 mM | 0.0261 mL | 0.1306 mL | 0.2612 mL | 0.6529 mL | |
| 100 mM | 0.0209 mL | 0.1045 mL | 0.2089 mL | 0.5223 mL |
Silatecan Related Classifications
HY-16055 Related Classifications
Powered by Bioz